Recruiting
PHASE1
INTERVENTIONAL
NCT06719011
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study medicine called "cagrilintide" or a placebo (a "dummy medicine" similar to the new study medicine and study medicine but without active ingredients). Which treatment participants will get is decided by chance. The new study medicine and the study medicine are potential new medicines which cannot be prescribed by doctors. This study will last for about a year in total.
Interventions
Name:
NNC0174-1213 A
Type:
DRUG
Description:
Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.
Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Name:
Cagrilintide B
Type:
DRUG
Description:
Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.
Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Name:
Placebo A (NNC0174 1213 A)
Type:
DRUG
Description:
Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection.
Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Primary Outcomes
Measure:
Part A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213
TimeFrame:
From NNC0174 1213 administration (Day 1) to completion of the end of study visit (Day 46)
Description:
Number of events
Measure:
Part B: Number of treatment emergent adverse events (TEAE)
TimeFrame:
From first administration (Day 1) to completion of the end of study visit (Day 67)
Description:
Number of events
Trial Information
NCT ID
NCT06719011
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025